Obesity treatment enters the transplant pathway for advanced kidney disease
Access to kidney transplantation is often narrowed long before a surgical waitlist is considered, and excess body weight is one of the barriers that can push eligible patients to the margins of care. In advanced chronic kidney disease, weight management is not a cosmetic issue or a secondary counseling topic; it can determine whether a person is considered for transplantation at all. The OK-TRANSPLANT 2 trial is designed around that reality, testing whether a structured, multicomponent obesity intervention can be delivered inside routine care for adults with advanced CKD, including those receiving dialysis.
The study is being run as a pragmatic, open-label randomized controlled trial. Its emphasis is not simply on whether participants lose weight, but on whether a real-world program can be recruited, delivered, adhered to, and tolerated in a population that has routinely been left out of major obesity trials. That gap matters because the biology of advanced kidney disease complicates weight management: fluid shifts, dietary restrictions, fatigue, and multiple comorbidities all make standard obesity programs harder to sustain. A transplant-focused intervention has to work in that setting, not in an idealized one.
Semaglutide, coaching, and lifestyle counseling form the core intervention
The intervention combines monthly virtual coaching with semaglutide titrated to a maximum dose of 2.0 mg/week, along with behavioral, dietary, and exercise counseling. The package is deliberately broad. In people with advanced CKD, medication alone is unlikely to address the practical barriers to weight loss, while counseling without pharmacologic support may be too weak to move body weight meaningfully. A bundled model is therefore being tested as a single clinical strategy rather than as separate fragments.
Semaglutide is biologically plausible in this setting because appetite suppression and slower gastric emptying can reduce caloric intake without requiring the sort of vigorous physical activity that is often unrealistic for people on dialysis or managing severe CKD symptom burden. But the trial is not assuming pharmacology will solve everything. The virtual coaching component is meant to keep patients engaged over 26 weeks, when early enthusiasm often gives way to treatment fatigue, transport problems, or competing medical appointments. Behavioral support may be especially relevant where weight loss carries a direct administrative consequence: improved transplant eligibility.
The trial is also open-label, which fits the care model but creates a familiar tradeoff. Both clinicians and participants know which treatment is being given, a design that improves feasibility in routine care while leaving the study vulnerable to expectation effects. For a pragmatic trial embedded in usual practice, that is not a flaw so much as a reflection of the clinical question: can this be done in the real world, and can it be done well enough to justify a larger definitive evaluation?
Recruitment targets are central because feasibility is the first endpoint
Adults aged 18 years or older are eligible if they have a body mass index of at least 35 kg/m2, with or without diabetes, and either are receiving dialysis or have more than 10% risk of end-stage kidney disease requiring renal replacement therapy over two years based on the Kidney Failure Risk Equation. The primary success criterion is recruitment of at least 50 participants, representing 83% of the target, within 12 months of site initiation.
That benchmark says a great deal about the purpose of the vanguard phase. This is not yet a full efficacy trial built to settle the clinical question once and for all. It is a test of whether the trial machinery can actually function in a group where obesity treatment has historically been under-tested and where competing medical priorities are constant. In patients already burdened by advanced kidney disease, recruitment itself becomes a clinical signal: if the intervention cannot be offered efficiently, it is unlikely to scale to the transplant programs that need it most.
Feasibility, adherence, safety, and selected efficacy outcomes will be summarized descriptively. The acceptability of the intervention will be explored using qualitative methods, which is particularly relevant here because success will depend not only on lab values or scale readings, but on how patients experience the program. A dialysis schedule, travel burden, appetite changes, and medication tolerance all shape whether an obesity intervention is lived as support or as another demand layered onto an already intense care routine.
Safety questions sit close to the center of the design
A weight management study in advanced CKD raises immediate safety questions that ordinary obesity trials rarely need to confront. Semaglutide-related gastrointestinal effects can threaten adherence, and any reduction in oral intake has to be interpreted carefully in patients with limited physiologic reserve. Fluid status, dialysis timing, nutritional adequacy, and intercurrent illness can all blur the line between expected treatment effect and clinically meaningful intolerance.
The trial design reflects those concerns by embedding the work in routine care and by keeping the intervention duration to 26 weeks for the vanguard phase. That window is long enough to detect early feasibility problems, but short enough to identify whether the program can be deployed before a larger study is attempted. In a transplant-oriented population, the practical question is not only whether weight falls, but whether the intervention can help patients move closer to listing without introducing new risks that offset the benefit.
The study began in September 2024 and is scheduled for completion in December 2027. Its registration number is NCT06396416. Because this is a protocol paper rather than an outcomes report, no clinical efficacy claims can be made yet. The main value of the vanguard phase is narrower and more immediate: it will show whether a semaglutide-centered, coaching-supported obesity program can be recruited and delivered to people with advanced CKD in a way that is realistic enough to justify the next stage of testing.